LEPR and ovarian cancer: The main aim of this study was to determine the possible use of the leptin receptor blockers superactive human leptin antagonist (SHLA) and quadruple leptin mutein, Lan-2 (L39A/D40A/F41A/I42A), as additional therapy factors for the treatment of ovarian cancer.